Labcorp outlays up to $872m to acquire BioReference’s laboratory assets

Labcorp said the agreement will help to improve access to its own laboratory services. Labcorp said the agreement will help to improve access to its own laboratory services. Labcorp anticipates that the acquisition will help it to expand its own laboratory testing provisions. Credit: Jennie Book/Shutterstock.com Labcorp is outlaying up to $872m to acquire certain laboratory assets from OPKO Health subsidiary BioReference Health, including its commercial 4Kscore blood test for aggressive prostate cancer prediction. Under the agreement, Labcorp will pay $722m in cash up front to acquire BioReference’s laboratory diagnostics businesses that focus on clinical and women’s health testing services,…

Source: Medical Device Network